Former Philips Executive Named Chief Commercial Officer at Vesalio

Vesalio has welcomed Greg Cook as chief commercial officer (CCO), responsible for leading Vesalio’s commercial strategy, market development, sales, marketing, and commercial operations. He is expected to play a key role in supporting Vesalio’s commercial expansion as the company advances its thrombectomy platform across neurovascular, coronary, and peripheral vascular markets.

“Greg brings the commercial leadership, market development expertise, and physician relationships that align with Vesalio’s strategic priorities,” Vesalio CEO Steve Rybka said. “His experience building commercial organizations and introducing technologies to treat vascular disease will be a valuable asset as we expand our thrombectomy platform, which uniquely addresses the full range of challenges in clot capture and removal.”

With more than 20 years of progressive medical device experience, Cook most recently served as senior vice president of Sales at Philips Image Guided Therapy Devices, where he led U.S. commercialization of the VeriSight intracardiac echocardiography platform. He previously led Philips’ Cardiac Lead Management sales organization. Throughout his career, Cook has partnered closely with physicians and cross-functional teams to build commercial organizations that support the adoption of new technologies.

“I am excited to join Vesalio and work alongside a team committed to advancing thrombectomy management,” Cook stated. “Vesalio’s commitment to clinical innovation and physician partnership creates a strong foundation for continued growth, and I look forward to expanding access to technologies that improve patient outcomes.”

Greg earned a bachelor of science degree in civil engineering from Texas A&M University and an MBA from Southern Methodist University.

Vesalio is a privately held medical device company advancing patient care for thromboembolic vascular disease by providing physicians with superior technology to improve clinical outcomes. Vesalio’s proprietary NeVa, enVast, and pVasc platforms are designed to effectively remove all types of clots and restore vital blood flow to compromised ischemic tissue in the brain, heart, and peripheral anatomy. Vesalio’s products have treated more than 19,000 patients in over 60 countries.